Search Results

You are looking at 1 - 2 of 2 items for

  • Author or Editor: Glenna M. Gobar x
  • Refine by Access: All Content x
Clear All Modify Search


Objective—To quantify incidence of vaccination practices, postvaccinal reactions, and vaccine site-associated sarcomas in cats.

Design—Epidemiologic survey.

Animals—31,671 cats vaccinated in the United States and Canada by veterinarians with World Wide Web access.

Procedure—Veterinarians used secure Web-based survey forms to report data regarding administered vaccines, postvaccinal inflammatory reactions, vaccine site-associated sarcomas, and detailed information and history on each sarcoma. Data were collected from Jan 1, 1998 to Dec 31, 2000, allowing a 1- to 3-year follow-up of vaccinated cats.

Results—Participants reported administering 61,747 doses of vaccine to 31,671 cats; postvaccinal inflammatory reactions developed in 73 cats (11.8 reactions/ 10,000 vaccine doses), and qualifying vaccine site-associated sarcomas developed in 2 cats (0.63 sarcomas/10,000 cats; 0.32 sarcomas/10,000 doses of all vaccines).

Conclusions and Clinical Relevance—These findings indicate that the incidence of vaccine site-associated sarcomas is low and is not increasing. Thoughtful consideration of the relative risks and benefits of specific vaccines remains the best means of reducing the incidence of sarcomas. It is not necessary to remove postvaccinal granulomas unless malignant behavior is apparent or they persist > 4 months. (J Am Vet Med Assoc 2002;220:1477–1482)

Full access
in Journal of the American Veterinary Medical Association


Objective—To determine whether particular vaccine brands, other injectable medications, customary vaccination practices, or various host factors were associated with the formation of vaccine-associated sarcomas in cats.

Design—Prospective multicenter case-control study.

Animals—Cats in the United States and Canada with soft tissue sarcomas or basal cell tumors.

Procedure—Veterinarians submitting biopsy specimens from cats with a confirmed diagnosis of soft tissue sarcoma or basal cell tumor were contacted for patient medical history. Time window statistical analyses were used in conjunction with various assumptions about case definitions.

Results—No single vaccine brand or manufacturer within antigen class was found to be associated with sarcoma formation. Factors related to vaccine administration were also not associated with sarcoma development, with the possible exception of vaccine temperature prior to injection. Two injectable medications (long-acting penicillin and methyl prednisolone acetate) were administered to case cats more frequently than to control cats.

Conclusions and Clinical Relevance—Findings do not support the hypotheses that specific brands or types of vaccine within antigen class, vaccine practices such as reuse of syringes, concomitant viral infection, history of trauma, or residence either increase or decrease the risk of vaccineassociated sarcoma formation in cats. There was evidence to suggest that certain long-acting injectable medications may also be associated with sarcoma formation. (J Am Vet Med Assoc 2003;223:1283–1292)

Full access
in Journal of the American Veterinary Medical Association